Whether a treatment option may be added to the hormone-sensitive metastatic prostate cancer treatment environment that lacked options is gaining attention.

According to industry officials, Astellas Korea applied for the extended insurance benefit of its anticancer drug ‘Xtandi (enzalutamide)’ in combination with androgen deprivation therapy (ADT). The agenda is expected to be deliberated at the National Health Insurance Service’s Cancer Disease Deliberation Committee meeting in January.

The company applied for the indication to treat ‘metastatic hormone-sensitive prostate cancer (mHSCP),’ an area where a great unmet need remains.

ADT+docetaxel, a standard therapy opti